182 related articles for article (PubMed ID: 22847767)
1. Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group.
Appel BE; Chen L; Buxton A; Wolden SL; Hodgson DC; Nachman JB
Pediatr Blood Cancer; 2012 Dec; 59(7):1284-9. PubMed ID: 22847767
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.
Marks LJ; Pei Q; Bush R; Buxton A; Appel B; Kelly KM; Schwartz CL; Friedman DL
Pediatr Blood Cancer; 2018 Dec; 65(12):e27375. PubMed ID: 30277639
[TBL] [Abstract][Full Text] [Related]
3. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.
Appel BE; Chen L; Buxton AB; Hutchison RE; Hodgson DC; Ehrlich PF; Constine LS; Schwartz CL
J Clin Oncol; 2016 Jul; 34(20):2372-9. PubMed ID: 27185849
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.
Nachman JB; Sposto R; Herzog P; Gilchrist GS; Wolden SL; Thomson J; Kadin ME; Pattengale P; Davis PC; Hutchinson RJ; White K;
J Clin Oncol; 2002 Sep; 20(18):3765-71. PubMed ID: 12228196
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group.
Wolden SL; Chen L; Kelly KM; Herzog P; Gilchrist GS; Thomson J; Sposto R; Kadin ME; Hutchinson RJ; Nachman J
J Clin Oncol; 2012 Sep; 30(26):3174-80. PubMed ID: 22649136
[TBL] [Abstract][Full Text] [Related]
6. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.
Charpentier AM; Friedman DL; Wolden S; Schwartz C; Gill B; Sykes J; Albert-Green A; Kelly KM; Constine LS; Hodgson DC
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):943-950. PubMed ID: 27869096
[TBL] [Abstract][Full Text] [Related]
7. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group.
Tebbi CK; Mendenhall NP; London WB; Williams JL; Hutchison RE; Fitzgerald TJ; de Alarcón PA; Schwartz C; Chauvenet A
Pediatr Blood Cancer; 2012 Dec; 59(7):1259-65. PubMed ID: 22911615
[TBL] [Abstract][Full Text] [Related]
8. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.
Hall GW; Katzilakis N; Pinkerton CR; Nicolin G; Ashley S; McCarthy K; Daw S; Hewitt M; Wallace WH; Shankar A
Br J Haematol; 2007 Sep; 138(6):761-8. PubMed ID: 17760808
[TBL] [Abstract][Full Text] [Related]
9. Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin lymphoma.
Huynh-Le MP; Walker AJ; Kominers SD; Paz-Priel I; Wharam MD; Terezakis SA
Pediatr Blood Cancer; 2014 Jul; 61(7):1210-4. PubMed ID: 24523203
[TBL] [Abstract][Full Text] [Related]
10. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.
Kelly KM; Sposto R; Hutchinson R; Massey V; McCarten K; Perkins S; Lones M; Villaluna D; Weiner M
Blood; 2011 Mar; 117(9):2596-603. PubMed ID: 21079154
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.
Wirth A; Yuen K; Barton M; Roos D; Gogna K; Pratt G; Macleod C; Bydder S; Morgan G; Christie D
Cancer; 2005 Sep; 104(6):1221-9. PubMed ID: 16094666
[TBL] [Abstract][Full Text] [Related]
12. ABVD or BEACOPP
Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
[TBL] [Abstract][Full Text] [Related]
13. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.
Mauz-Körholz C; Gorde-Grosjean S; Hasenclever D; Shankar A; Dörffel W; Wallace WH; Schellong G; Robert A; Körholz D; Oberlin O; Hall GW; Landman-Parker J
Cancer; 2007 Jul; 110(1):179-85. PubMed ID: 17526010
[TBL] [Abstract][Full Text] [Related]
14. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group.
Kung FH; Schwartz CL; Ferree CR; London WB; Ternberg JL; Behm FG; Wharam MD; Falletta JM; de Alarcon P; Chauvenet AR;
J Pediatr Hematol Oncol; 2006 Jun; 28(6):362-8. PubMed ID: 16794504
[TBL] [Abstract][Full Text] [Related]
15. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.
Schwartz CL; Chen L; McCarten K; Wolden S; Constine LS; Hutchison RE; de Alarcon PA; Keller FG; Kelly KM; Trippet TA; Voss SD; Friedman DL
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786406
[TBL] [Abstract][Full Text] [Related]
16. [A single-center retrospective analysis of 85 children and adolescents with limited-stage Hodgkin lymphoma].
Wu B; Wang J; Zhu J; Zhen ZZ; Lu SY; Sun FF; Huang JT; Sun XF
Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):649-654. PubMed ID: 32942818
[No Abstract] [Full Text] [Related]
17. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.
Keller FG; Castellino SM; Chen L; Pei Q; Voss SD; McCarten KM; Senn SL; Buxton AB; Bush R; Constine LS; Schwartz CL
Cancer; 2018 Aug; 124(15):3210-3219. PubMed ID: 29738613
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible?
Laskar S; Kumar DP; Khanna N; Menon H; Sengar M; Arora B; Gujral S; Shet T; Sridhar E; Rangarajan V; Muckaden MA; Nair R; Banavali S
Leuk Lymphoma; 2014 Oct; 55(10):2356-61. PubMed ID: 24354681
[TBL] [Abstract][Full Text] [Related]
20. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.
Hoppe BS; Flampouri S; Zaiden R; Slayton W; Sandler E; Ozdemir S; Dang NH; Lynch JW; Li Z; Morris CG; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1053-1059. PubMed ID: 24928256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
